BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31691080)

  • 1. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
    Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
    El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
    Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats.
    Shibayama Y; Ushinohama K; Ikeda R; Yoshikawa Y; Motoya T; Takeda Y; Yamada K
    Cancer Sci; 2006 Nov; 97(11):1260-6. PubMed ID: 16925582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate.
    Jia Y; Liu Z; Wang C; Meng Q; Huo X; Liu Q; Sun H; Sun P; Yang X; Ma X; Liu K
    Toxicol Appl Pharmacol; 2016 Sep; 306():27-35. PubMed ID: 27377006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Methotrexate Uptake via Organic Anion Transporters OAT1 and OAT3 by Glucuronides of Nonsteroidal Anti-inflammatory Drugs.
    Iwaki M; Shimada H; Irino Y; Take M; Egashira S
    Biol Pharm Bull; 2017; 40(6):926-931. PubMed ID: 28566636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
    Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
    Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
    Elsby R; Fox L; Stresser D; Layton M; Butters C; Sharma P; Smith V; Surry D
    Eur J Pharm Sci; 2011 May; 43(1-2):41-9. PubMed ID: 21440623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2.
    Liao XY; Deng QQ; Han L; Wu ZT; Peng ZL; Xie Y; Wang GJ; Aa JY; Pan GY
    Acta Pharmacol Sin; 2020 Jan; 41(1):129-137. PubMed ID: 31341258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of hydroxycinnamic acids and their conjugates with organic anion transporters and ATP-binding cassette transporters.
    Wong CC; Barron D; Orfila C; Dionisi F; Krajcsi P; Williamson G
    Mol Nutr Food Res; 2011 Jul; 55(7):979-88. PubMed ID: 21538853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro.
    Liu Q; Liu Z; Huo X; Wang C; Meng Q; Sun H; Sun P; Peng J; Ma X; Liu K
    Biomed Pharmacother; 2018 Jul; 103():915-922. PubMed ID: 29710508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions Between Meropenem and Renal Drug Transporters.
    Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
    Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
    Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
    Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3.
    Chioukh R; Noel-Hudson MS; Ribes S; Fournier N; Becquemont L; Verstuyft C
    Drug Metab Dispos; 2014 Dec; 42(12):2041-8. PubMed ID: 25239859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP).
    Markowicz-Piasecka M; Huttunen J; Montaser A; Adla SK; Auriola S; Lehtonen M; Huttunen KM
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
    J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
    Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
    Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
    Li L; Agarwal S; Elmquist WF
    Drug Metab Dispos; 2013 Mar; 41(3):659-67. PubMed ID: 23297298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.